Entities / Company
Delcath Systems, Inc..
Company
- Reports this week
- 1
- Active events
- 0
- Connections
- 18
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Delcath Systems, Inc. is treating liver cancers in the United States and Europe.Some support3 reports
-
Incepta Pharmaceuticals and Delcath Systems, Inc. are involved in a new industry ranking.Some support1 report
-
Delcath Systems, Inc., led by CEO Gerard Michel, received authorization for clinical studies in the UK and EU.Some support1 report
-
Delcath Systems, Inc. reported that its accrual ratio was -0.11 and free cash flow exceeded statutory profit.Some support1 report
-
The FDA regulated HEPZATO KIT, a drug associated with Delcath Systems, Inc.Some support5 reports
-
Delcath Systems, Inc. reported a low Return on Equity (ROE) compared to the industry average.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Delcath Systems, Inc. this week
News at the entities that move Delcath Systems, Inc. most-
FDA StructuralNRx Pharmaceuticals is undergoing a first-cycle review of an ANDA for ketamine, noting its strategic importance for the U.S. military and VA.Moves Delcath Systems, Inc.
-
Europe Shared contextDouglas Murray commented on the decline of Europe while Brussels continued to exert bureaucratic pressure on the continent.Moves Delcath Systems, Inc.
-
Curaleaf Mentioned togetherCuraleaf, led by Boris Jordan, partnered with Rivera to establish a training program in New York.Moves Delcath Systems, Inc.
Connections
The 6 strongest of 18, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA formally regulates and approves products developed by Delcath Systems, Inc., determining market access.
-
Gerard Michel Structural
Gerard Michel serves as the Chief Executive Officer of Delcath Systems, Inc.
-
IMRIS Operational
The two medical companies are currently engaged in market competition.
-
Europe Shared context
Delcath Systems operates, conducts clinical trials, and seeks sales in the European market.
-
Curaleaf Mentioned together
Both companies are noted as healthcare entities facing market scrutiny.
-
NeoGen Mentioned together
Both companies are mentioned together in the context of being compared within the healthcare sector.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
1 eventJune 2026
6 events- Delcath Systems, Inc. is treating liver cancers in the United States and Europe.
- Incepta Pharmaceuticals and Delcath Systems, Inc. are involved in a new industry ranking.
- Delcath Systems, Inc., led by CEO Gerard Michel, received authorization for clinical studies in the UK and EU.
- Delcath Systems, Inc. reported that its accrual ratio was -0.11 and free cash flow exceeded statutory profit.
- The FDA regulated HEPZATO KIT, a drug associated with Delcath Systems, Inc.
- Delcath Systems, Inc. reported a low Return on Equity (ROE) compared to the industry average.